Management strategies for partially platinum-sensitive ovarian cancer

American Journal of Cancer

Volumn 5, Issue 5, 2006, Pages 341-354

  Ledermann, Jonathan A ^a,b   Raja, Fharat ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FATIGUE; FLU LIKE SYNDROME; GENE MUTATION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SENSORY NEUROPATHY; SEPSIS; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

EID: 33846859308     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605050-00005     Document Type: Review

References (79)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51 (1): 15-36
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334 (1): 1-6
3. Rustin GJ, Van der Burg ME, Berek JS. Advanced ovarian cancer: tumour markers. (review). Ann Oncol 1993; 4 Suppl. 4: 71-7
4. Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-3
5. Gore M, Fryatt I, Wiltshaw E, et al. Treatment of relapsed ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-11
6. Gore ME, Fryatt I, Wiltshaw E, et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989; 60 (5): 767-9
7. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9 (3): 389-93
8. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20 (5): 1232-7
9. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8 (10): 963-8
10. Sherman SE, Gibson D, Wang AH, et al. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Science 1985; 230 (4724): 412-7
11. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985; 55 (10): 2303-16
12. Masuda H, Tanaka T, Matsuda H, et al. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis- diamminedichloroplatinum(II). Cancer Res 1990; 50 (6): 1863-6
13. Freitas S, Moore DH, Michael H, et al. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res 2003; 9 (13): 4689-94
14. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24 (5): 331-44
15. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000; 20 (2A): 645-52
16. Dabholkar M, Thornton K, Vionnet J, et al. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 2000; 60 (11): 1611-9
17. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993; 90 (11): 4961-5
18. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56 (4): 689-93
19. Wen WH, Reles A, Runnebaum IB, et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999; 18 (1): 29-41
20. Rutz HP. Cancer therapy meets p53. N Engl J Med 1994; 331 (19): 1314-5
21. Markman M, Blessing JA, Moore D, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998 Jun; 69 (3): 226-9
22. McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18 (5): 1062-7
23. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15 (3): 987-93
24. Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18 (6): 1193-202
25. Seymour MT, Mansi JL, Gallagher CJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69 (1): 191-5
26. Sorensen P, Hoyer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 2001; 81 (1): 58-62
27. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian cancer after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-53
28. Vermorken JB, Kobierska A, Chevallier B, et al. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin: EORTC Gynecological Cancer Cooperative Group. Ann Oncol 2000; 11 (8): 1035-40
29. von Minckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999; 10 (7): 853-5
30. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11 (12): 2405-10
31. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15 (6): 2183-93
32. ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15 (1): 100-3
33. National Institute for Health and Clinical Excellence. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second or subsequent treatment of advanced ovarian cancer [online]. Technology appraisal 91; London, 2005. Available from URL: http://www.nice.org.uk/TA091 [Accessed 2005 Aug 17]
34. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002; 38 (1): 57-63
35. Vermorken JB. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer 2003; 13 Suppl. 2: 178-84
36. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19 (14): 3312-22
37. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95 (1): 1-8
38. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998; 9 (12): 1343-5
39. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86 (20): 1530-3
40. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003; 90 (3): 593-6
41. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16 (2): 405-10
42. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv Exp Med Biol 1994; 370: 139-43
43. Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating roublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol, 2003; 88 (1): 35-9
44. Rose PG, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003; 88 (1): 17-21
45. du Bois A, Luck HJ, Pfisterer J, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer: a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001; 12 (8): 1115-20
46. Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. Gynecol Oncol 2004; 92 (1): 152-9
47. Goldberg JM, Piver MS, Hempling RE, et al. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1996; 63 (3): 312-7
48. Rose PG, Fusco N, Fluellen L, et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16 (4): 1494-7
49. Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: the Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2003; 91 (3): 584-90
50. The ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators: International Collaborative Ovarian Neoplasm Study. Lancet 1998 Nov 14; 352 (9140): 1571-6
51. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9 (9): 1668-74
52. Bolis G, Scarfone G, Giardina G, et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001; 81 (1): 3-9
53. Ferrero JM, Weber B, Lepille D, et al. Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): survival results of a GINECO phase II trial [abstract]. J Clin Oncol 2004; 22 Suppl. 14: 5022
54. Vorobiof DA, Rapoport B, Slabber C, et al. Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer [abstract]. J Clin Oncol 2004; 22 Suppl. 14: 5091
55. International Collaboration for Ovarian Neoplasia Group. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361 (9375): 2099-106
56. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin vs carboplatin in platinum sensitive recurrent ovarian cancer: results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol. In press
57. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360 (9332): 505-15
58. Cassinelli G, Supino R, Perego P, et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 2001; 92 (5): 738-47
59. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95 (17): 1320-9
60. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96 (22): 1682-91
61. ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov/ct/show/nct00189553 [Accessed 2006 Aug 17]
62. Skarlos DV, Kalofonos HP, Fountzilas G, et al. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes: a HeCOG phase II study. Anticancer Res 2005; 25 (4): 3103-8
63. Ferrandina G, Paris I, Ludovisi M, et al. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol 2005; 98 (2): 267-73
64. Garcia AA, O'Meara A, Bahador A, et al. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 2004; 93 (2): 493-8
65. Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002; 41 (5): 418-24
66. Rose PG, Smrekar M, Fusco N. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 2005; 96 (2): 296-300
67. Havrilesky LJ, Alvarez AA, Sayer RA, et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003; 88 (1): 51-7
68. de Jongh FE, de Wit R, Verweij J, et al. Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 2002; 38 (15): 2005-13
69. van der Burg ME, de Wit R, van Putten WL, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002; 86 (1): 19-25
70. Meyer T, Nelstrop AE, Mahmoudi M, et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 2001; 12 (12): 1705-9
71. Stiff PJ, Veum-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000; 133 (7): 504-15
72. Ledermann J, Herd R, Maraninchi D, et al. High dose chemotherapy in ovarian cancer: an analysis of the experience of the European Group for Blood and Marrow Transplant (EBMT) over 7 years [abstract no. 1391]. Proc Am Soc Clin Oncol 1999; 18: 360
73. Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13 (7): 1584-8
74. Monk BJ, Han E, Josephs-Cowan CA, et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006 Aug; 102 (2): 140-4
75. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005 Sep-Oct; 15 (5): 785-92
76. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005 Aug; 11 (15): 5539-48
77. Current Controlled Trials. ISRCTN 87786644 [online]. Available from URL: http://www.controlledtrials.com [Accessed 2006 Aug 18]
78. Donovan KA, Greene PG, Shuster JL, et al. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002; 86 (2): 200-11
79. Holzner B, Kemmler G, Meraner V, et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 2003; 97 (6): 1564-72